de Oliveira R S
Arq Neuropsiquiatr. 1979 Mar;37(1):48-52. doi: 10.1590/s0004-282x1979000100007.
Mogadon as a parenteral solution was employed for treating status epilepticus (15 cases), intermitent epileptic seizures (10 cases), Lennox syndrome (14 cases), myoclonic seizures (5 cases) and absences (6 cases). The dosage layed between 3,3 mg and 10 mg according to each individual case. Status epilepticus and intermitent seizures disappeared following the injection and so did the irritative EEG alterations. Remission was observed in 10 Lennox cases while the remaining 4 improved. Mogadon abolished myoclonic seizures, in some cases beyond 6 hours. In simple absence improvement was also evident, although more shortlived than in myoclonic seizures. Sleepiness was side-effect, occurring in some cases.
速可眠作为一种胃肠外溶液用于治疗癫痫持续状态(15例)、间歇性癫痫发作(10例)、伦诺克斯综合征(14例)、肌阵挛性发作(5例)和失神发作(6例)。根据每个病例的情况,剂量在3.3毫克至10毫克之间。注射后癫痫持续状态和间歇性发作消失,刺激性脑电图改变也消失。10例伦诺克斯综合征病例病情缓解,其余4例有所改善。速可眠消除了肌阵挛性发作,在某些情况下作用超过6小时。在单纯失神发作中也有明显改善,尽管比肌阵挛性发作持续时间更短。嗜睡是副作用,在某些情况下会出现。